Veracyte to replace Triumph in S&P SmallCap 600 index; VCYT shares up 6.49% pre-market.

Veracyte, a biotechnology company, is set to replace Triumph Group in the S&P SmallCap 600 index due to Triumph's acquisition by private equity firms Warburg Pincus and Berkshire Partners. Veracyte shares rose 6.49% pre-market on Friday, while Triumph's deal is expected to close soon.

Veracyte Inc. (NASDAQ: VCYT), a biotechnology company specializing in genomic diagnostics, is set to replace Triumph Group Inc. (NYSE: TGI) in the S&P SmallCap 600 index. This change will take effect prior to the market open on Tuesday, July 29, 2025. The announcement comes as private equity firms Warburg Pincus LLC and Berkshire Partners LLC are in the process of acquiring Triumph Group, with the deal expected to close soon [1].

Veracyte shares rose 6.49% in pre-market trading on Friday, July 24, 2025, following the news of its inclusion in the S&P SmallCap 600 index. The index addition is likely to drive further interest in Veracyte's shares, as funds tracking the benchmark will need to purchase shares of the newly added company [2].

The S&P SmallCap 600 index is a widely followed benchmark that tracks the performance of the small-cap segment of the U.S. equity market. The index is known for its liquidity and represents a broad range of small-cap companies across various sectors. Veracyte's addition to the index is expected to increase its visibility among investors and potentially drive further growth in its stock price [3].

Veracyte's inclusion in the S&P SmallCap 600 index marks a significant milestone for the company. It follows a series of strong financial results and strategic expansions, including robust growth in its market-leading Decipher Prostate and Afirma tests. The company reported an 18% revenue increase in the first quarter of 2025, driven by strong testing volumes and strategic product launches [4].

In contrast, Triumph Group's removal from the S&P SmallCap 600 index is a result of its acquisition by Warburg Pincus LLC and Berkshire Partners LLC. The acquisition is expected to close soon, pending final closing conditions. Triumph Group operates in the industrials sector and provides a range of services, including aerospace and defense solutions [1].

The change in the S&P SmallCap 600 index is a reflection of the dynamic nature of the small-cap market, where companies frequently enter and exit the index due to mergers and acquisitions, as well as changes in their financial performance and market capitalization. Veracyte's inclusion in the index is a testament to its strong financial performance and potential for growth in the genomic diagnostics market [3].

References:
[1] https://www.prnewswire.com/news-releases/veracyte-set-to-join-sp-smallcap-600-600-302513607.html
[2] https://seekingalpha.com/news/4472109-veracyte-to-replace-triumph-in-sp-smallcap-600-index
[3] https://finance.yahoo.com/quote/VCYT/news/
[4] https://www.investing.com/news/stock-market-news/veracyte-stock-soars-after-sp-smallcap-600-addition-93CH-4153361